Sign In
Buy VYNE
$0.656
-0.0200 (-2.96%)
At Close: Jun 03, 2026
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
10:16am, Thursday, 09'th May 2024
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $1.74 per share a year ago.
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
08:00am, Thursday, 09'th May 2024
BRIDGEWATER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietar
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
08:00am, Monday, 06'th May 2024
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic mode
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
08:00am, Wednesday, 01'st May 2024
BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovati
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
08:00am, Tuesday, 19'th Mar 2024
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing propriet
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
10:56am, Wednesday, 13'th Mar 2024
After losing some value lately, a hammer chart pattern has been formed for VYNE Therapeutics Inc. (VYNE), indicating that the stock has found support. This, combined with an upward trend in earnings e
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
01:01pm, Friday, 08'th Mar 2024
VYNE Therapeutics Inc. (VYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
08:00am, Thursday, 29'th Feb 2024
BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprieta
BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovat
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
08:00am, Wednesday, 21'st Feb 2024
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovat
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
08:00am, Wednesday, 10'th Jan 2024
BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovat
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
08:00am, Wednesday, 03'rd Jan 2024
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovat
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
07:45am, Monday, 13'th Nov 2023
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
08:00am, Tuesday, 07'th Nov 2023
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE's clinical development plans
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:19am, Thursday, 02'nd Nov 2023
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
